【Hot antibody recommendations】Biolab Reagents Agent：Research Gra

临床Ficlatuzumab抗体的应用：

Ficlatuzumab（AV-299）为人源化 IgG1 抗体，以较高的亲和性与 HGF 配体结合并特异性抑制 HGF/MET 活化。临床前模型显示，该药物具有较强的抗肿瘤活性，并以剂量依赖方式降低肿瘤的生长且显著减少肿瘤裂解物中 c-Met 和 AKT 磷酸化水平。 I 期临床试验数据显示，Ficlatuzumab 与表皮生长因子受体（EGFR）抑制剂埃罗替尼和吉非替尼联用具有良好的耐受性，并给出 II 期建议剂量：每 2 周 20 mg/kg。Ficlatuzumab 单药治疗最常见的毒性为疲劳、外周性水肿、头痛、腹泻；联合治疗的主要副作用为皮疹和腹泻。 2012 年的欧洲社会医学肿瘤会议（ESMO）中展示出一项探索性随机化 II 期临床研究结果，该研究对 ficlatuzumab 联合吉非替尼与吉非替尼单药用于未经治疗的非小细胞肺癌（NSCLC）亚洲患者治疗效果进行了对比评价。该项研究并未达到其主要终点（总体响应率）。 然而，ficlatuzumab 联合吉非替尼似乎提高了低 MET 表达子集患者中位无进展生存期（PFS），并延长高基质 HGF 和其他生物标志物子集患者总生存期（OS）。

科研型Ficlatuzumab

货号：DHD03701

产品介绍：Ficlatuzumab是一种靶向人肝细胞生长因子(HGF)的单克隆抗体 (McAb)。Ficlatuzumab能够阻断HGF/c-Met信号通路的激活，抑制c-Met受体介导的癌细胞增殖、迁移和侵袭。

通用名:Ficlatuzumab

纯度:>95% by SDS-PAGE.

浓度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

内毒素:Please contact with the lab for this information.

别名:AV-299, SCH 900105

靶点;物种:Human HGF

种类:Humanized

受体鉴定:IgG1-kappa

CAS: 1174900-84-5

存储条件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

参考文献：

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. PMID: 24901237

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. PMID: 32545260

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. PMID: 34514432

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. PMID: 29346833

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. PMID: 24634378

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. PMID: 23493885

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. PMID: 26540318

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. PMID: 27448761

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. PMID: 36807743

Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI. PMID: 23983258

A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. PMID: 33725344

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. PMID: 36977289

Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. PMID: 30636579

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. PMID: 25217525

The emerging role of MET/HGF inhibitors in oncology. PMID: 23453860

C-MET inhibitors in the treatment of lung cancer. PMID: 25266653

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer. PMID: 33638808

Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. PMID: 27831000

Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib. PMID: 23715581

Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis. PMID: 36716856

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. PMID: 28209746

Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. PMID: 27569653